The 25 analysts offering 12-month price forecasts for Intellia Therapeutics Inc have a median target of 115.00, with a high estimate of 173.00 and a low estimate of 48.00. The median estimate represents a +149.57% increase from the last price of 46.08.
The current consensus among 28 polled investment analysts is to Buy stock in Intellia Therapeutics Inc. This rating has held steady since December, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.37
Reporting Date Mar 15
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.